Predicting drug resistance
A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.
Saved in:
| Main Authors: | Nicole S Arellano, Shannon E Elf |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eLife Sciences Publications Ltd
2024-11-01
|
| Series: | eLife |
| Subjects: | |
| Online Access: | https://elifesciences.org/articles/103775 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response
by: Rebecca Warfvinge, et al.
Published: (2024-11-01) -
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers
by: Anna Sicuranza, et al.
Published: (2025-05-01) -
Cytokines secreted from bone marrow-derived mesenchymal stem cells promote apoptosis of CD34+ leukemic stem cells as anti-cancer therapy
by: Raheleh Farahzadi, et al.
Published: (2024-06-01) -
ADA/CD26 axis increases intra-tumor PD-1+CD28+CD8+ T-cell fitness and affects NSCLC prognosis and response to ICB
by: Ornella Franzese, et al.
Published: (2024-12-01) -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)